



Press Release

Saturday, November 21, 2015

Strides Shasun Limited
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives US FDA approval for Dutasteride Softgel Capsule

Product ready for Day 1 launch

Bangalore, November 21, 2015 Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Dutasteride Capsules, 0.5 mg**. The product is ready for Day 1 launch.

According to IMS data, the US market for Dutasteride Capsules is approximately USD 470 Million. The product has gone off patent on November 20, 2015 and Strides Shasun is amongst the first wave of generic players to receive this approval.

The product will be manufactured at the Company's Oral dosage facility at Bangalore and marketed by Strides Shasun in the US Market.

About Dutasteride

Dutasteride is used to treat benign prostatic hyperplasia (BPH; enlargement of the prostate gland). Dutasteride is used to treat symptoms of BPH and may reduce the chance of developing acute urinary retention (sudden inability to urinate). Dutasteride may also decrease the chance that prostate surgery will be needed.

About Strides Shasun Limited

Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.

The Company has global manufacturing foot print with 12 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 6 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com.



For further information, please contact:

<u>Strides Shasun</u> Mohan Kumar, CEO - Pharma +91 80 6784 0748 Vikesh Kumar +91 80 6784 0827 Kannan N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
---	---

